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Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease causing death of
motor neurons. This study investigated the roles of energy metabolism in the pathogen-
esis of ALS in the SOD1(G93A) transgenic mouse model. Control and SOD1(G93A) mice
were administered with shcontrol or shPGC-1α in combination with PBS or thiazolidine-
dione (TZD) for 8weeks. Gene expression was analyzed by quantitative real-time PCR and
Western blot. ROS and fibrosis were assessed with a colorimetric kit and Sirius staining,
respectively. Inflammatory cytokines were measured using ELISA kits. The levels of tissue
ROS and serum inflammatory cytokines were significantly higher in SOD1(G93A) mice
compared to control mice, and knocking down peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α) drastically increased cytokine levels in both control
and SOD1(G93A) mice. Muscle fibrosis was much severer in SOD1(G93A) mice, and
worsened by silencing PGC-1α and attenuated by TZD. The expression levels of PGC-1α,
SOD1, UCP2, and cytochromeCwere substantially reduced by shPGC-1α and increased
by TZD in muscle of both control and SOD1(G93A) mice, whereas the level of NF-κB
was significantly elevated in SOD1(G93A) mice, which was further increased by PGC-1α
silencing. These data indicated that disruption of energy homeostasis would exacerbate
the pathological changes caused by SOD1 mutations to promote the pathogenesis
of ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease in the USA, is
a fatal neurodegenerative disease affecting motor neurons (Kiernan et al., 2011; Gordon, 2013).
Although the cause of most ALS cases is not known, more genetic defects associated with familial
ALS have been detected employing new technologies since the discovery of mutations in superoxide
dismutase 1 (SOD1) (Rosen et al., 1993). Combining large-scale DNA sequencing with genome-
wide association studies and linkage analysis, mutations in C9orf72 (DeJesus-Hernandez et al.,
2011; Daoud et al., 2012; Robberecht and Philips, 2013), TDP43 (Sreedharan et al., 2008), and
many other genes (Sreedharan and Brown, 2013) have been linked to or implicated in ALS.
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Among all the ALS-implicated genes, only SOD1 transgenic
rodentmodels ofALShave beenwidely investigated (Gurney et al.,
1994; Ripps et al., 1995; Dunlop et al., 2003).
The roles of mitochondrial dysfunction in the pathogenesis of
ALS have been recognized since the identification of structural
and morphological abnormalities in mitochondria from post-
mortem skeletal muscle, liver, spinal cord neurons, and motor
cortex of ALS patients (Hirano et al., 1984; Sasaki and Iwata,
1996, 1999). The defects in the activities of the electron transport
complexes emerged during the pre-symptomatic phase of disease
in the spinal cord of mutant SOD1 mice (Jung et al., 2002; Matti-
azzi et al., 2002; Kirkinezos et al., 2005; Vehviläinen et al., 2014).
Moreover, the impairments of mitochondria Ca2+ capacity and
oxidative phosphorylation precede the onset of ALS (Kong and
Xu, 1998; Damiano et al., 2006; Grosskreutz et al., 2010; Tan et al.,
2014; Vehviläinen et al., 2014).
Peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC-1α) is a transcriptional coactivator that regulates
a wide range of genes involved in mitochondrial biogenesis,
fatty acid oxidation, and oxidative metabolism (Wu et al., 1999;
Liang and Ward, 2006), which has been implicated in Hunting-
ton’s disease, Parkinson’s diseases, ALS, and other neurodegen-
erative diseases (Róna-Vörös and Weydt, 2010). PPARγ agonists
thiazolidinediones (TZDs) were shown to reduce hyperglycemia-
induced ROS production and promoted mitochondria biogene-
sis through activating PGC-1α pathway (Fujisawa et al., 2009).
Although the death of motor neurons is the most prominent
characteristics of ALS, the cytotoxicity of SOD1(G93A) caused
skeletal muscle atrophy might be an intrinsic characteristics of
ALS pathogenesis (Dobrowolny et al., 2008). This study aimed to
investigate the effect of manipulating PGC-1α pathway (activat-
ing PGC-1α by rosiglitazone or silencing PGC-1α) on the skeletal
muscle of SOD1(G93A) ALS mouse model.
MATERIALS AND METHODS
SOD1-G93A and C57BL/6 Mice
Four-week-old SOD1(G93A) mice (body weight about 75 g)
were purchased from the Nanjing biomedical research institute.
C57BL/6 mice were purchased from Yangzhou University. All
animal protocols were reviewed and approved by the Institutional
AnimalCare andUsageCommittee of The First Clinical College of
Harbin Medical University. The mice were kept in a temperature-
controlled (22–24°C) room with a 12-h light and 12-h dark cycle
and allowed to customize to the new environment for a week.
According to the different groups (10mice in each group), injected
PBS or rosiglitazone (GlaxoSmithKline, Philadelphia, PA, USA)
(10mg/kg body weight) with siControl or siPGC-1α through
tail-vein twice a week for 8weeks.
Lentiviral shRNA Targeting PGC-1α
The shRNA targeting 50-GGTGGATTGAAGTGGTGTAGA-3’
within mouse PGC-1α coding sequence (Koo et al., 2004) was
designed and cloned into pLL3.7 lentiviral vector (MIT) according
to the provider’s protocol. Lentiviruses (shPGC-1α and shCon-
trol) were packaged, purified, and tittered by syngentech (Beijing,
China).
Sirius Staining
Mouse gastrocnemius muscle tissue sections were stained with
a Picric acid – Sirius staining kit (Senbeijia Biotech, Nanjing,
China). The sections were washed three times in 1 PBS for
2min each, incubated with Sirius staining solution at room tem-
perature for 30min, and washed as before, counterstained with
hematoxylin for 5min, washed three times in PBS for 1–2min
each before being checked and photographed under an Olympus
ix71 microscope.
Western Blot
The total proteins from gastrocnemius muscle were separated
on a 12% SDS-polyacrylamide gel, transferred onto polyvinyli-
dene difluoride membranes (Bio-Rad, Hercules, CA, USA). The
membranes were blocked with 5% non-fat milk for 30min at
room temperature before being incubated with anti-PGC-1α
(ab191838, Abcam, Cambridge, MA, USA), PGC-1β (ab199228,
Abcam), SOD1 (ab52950, Abcam), UCP2 (ab77363, Abcam),
NF-κB (ab194786, Abcam), P38 (ab119916, Abcam), Cytochrome
C (ab133504, Abcam), or β-actin (ab194592, Abcam) antibodies
overnight at 4°C. After washing, the membranes were incubated
with horseradish peroxidase-conjugated secondary antibodies
(Jackson ImmunoResearch Lab, West Grove, PA, USA) for 1 h
at room temperature. The blots were then visualized using the
enhanced chemiluminescence kit (Pierce, Rockford, IL, USA).
Densitometry analysis was performed with a Hewlett-Packard
scanner and NIH Image software (Image J).
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was extracted from mouse gastrocnemius muscle
using RNeasy mini kits (Qiagen, Venlo, Netherlands). Reverse
transcription was performed with the SuperScript® III First-
Strand Synthesis System (Life Tech, Shanghai, China) according
to the supplier’s instructions using 1 g total RNA. Quantitative
real-time PCR was performed using the SYBR® Green PCR
Master Mix (Life Tech) on a ABI 7300 (Applied Biosystems,
Foster City, CA, USA) with the following program: 95°C for
3min followed by 40 cycles of 95°C for 30 s, 58°C for 15 s, and 68°C
for 30 s. The primers used were ACAGAGACACTGGACAGTCT
and CATTGTAGCTGAGCTGAGTG for PGC-1α, CCTC-
CTTCTTCCTCAACTAT and GTTGGGTTCAGTCTCTGAGT
for PGC-1β, ACTTCGAGCAGAAGGCAAGC and AACATG
CCTCTCTTCATCCG for SOD1, CTTCACTTCTGCCTTCGGG
and CCAGGATCCCAAGCGGAGA for UCP2, TGGGAAAC
CGTATGAGCCTG and GCAGAGTTGTAGCCTCGTGT for
NF-κB, GTTCAGAAGTGTGCCCAGTG and TACTCCATCA
GGGTATCCTC for cytochrome C, CCAGCTTAGGTTCATCA
GGTAA and ACACCGACCTTCACCATTTTG for GAPDH.
The relative transcription levels were calculated with the 2 ΔΔCt
method using GAPDH as the internal control.
Immunoprecipitation
Mouse gastrocnemius muscle was washed twice with ice cold PBS
and homogenized in 500μl RIPA lysis buffer followed by three
rounds of freeze-thaw. Tissue lysates were centrifuged for 5min
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FIGURE 1 | SOD1(G93A) and PGC-1α silencing increased ROS levels in
skeletal muscle. Mouse gastrocnemius muscle was homogenized in
100mmol/L phosphate buffer (pH 7.1) and centrifuged at 1000 g for 10min.
The supernatant (190μl) was mixed with 10μl of freshly made 1mmol/L
DCFH-DA working solution and incubated for 30min at 37°C before
measured at 500/525 nm (Ex/Em). Relative ROS levels were calculated with
ROS level of wild-type mice that received shcontrol and PBS being set as 1.
Data were expressed as meanSD (n= 10). *p<0.05 vs wild-type mice
treated with shControl and PBS; #p<0.05 vs SOD1(G93A) mice treated with
shControl and PBS; ^p<0.05 vs wild-type mice treated with shPGC-1α and
PBS; and +p<0.05 vs SOD1(G93A) mice treated with shPGC-1α and PBS.
at 14,000 rpm at 4°C, and cleared supernatant was transferred
into a new tube. For immunoprecipitations, 750μg total protein
was incubated with 5μg anti NF-κB p65 (ab16502, Abcam), p50
(ab7971, Abcam) antibodies, or normal rabbit IgG (negative con-
trol), respectively, at 4°C overnight with rotation. Immune com-
plexes were captured with 25μl of protein A/G resin (Pierce) and
incubated for 1 h at 4°C with rotation. Samples were washed four
times with lysis buffer with centrifugation for 5min at 2000 rpm
at 4°C. After final wash, the pellets were boiled 5min in 40μl of
2 SDS sample buffer and subjected to SDS-PAGE and Western
blot analysis.
Cytokine Levels Measured by ELISA
The serum TNF-α, IL-1β, IL6, TNF-α, and MIP-1a levels were
measured with specific ELISA kits (Elabscience, Wuhan, China)
according to the manufacturer’s instructions.
Measurement of Muscle ATP Level
Muscle ATP level was measured with a kit from Jianchen Biotech
(A095, Nanjing, China) according to the manufacturer’s protocol.
Briefly, mouse gastrocnemius muscle was homogenized in cold
PBS followed by three freeze-thaw cycles. Supernatant was used
for assay after lysates were centrifuged for 10min at 13,000 g at
4°C. Thirty microliters of supernatant was missed with 100μl
of Substrate Solution I, 200μl Substrate Solution II, and 30μl
Accelerant. The standard, blank, and controlwere set up according
to the protocol. The mixtures were incubated at 37°C for 30min
and then mixed with 50μl of Precipitant before being centrifuged
FIGURE 2 | PGC-1α knockdown exacerbated inflammation in
SOD1(G93A) mice. Mouse serum TNFα (A), IL-1β (B), IL-6 (C), and MIP-1α
(D) levels were measured with commercial ELISA kits. Data were expressed
as meanSD (n= 10). *p<0.05 vs wild-type mice treated with shControl
and PBS; #p<0.05 vs SOD1(G93A) mice treated with shControl and PBS;
^p<0.05 vs wild-type mice treated with shPGC-1α and PBS; and +p<0.05
vs SOD1(G93A) mice treated with shPGC-1α and PBS.
for 5min at 4000 rpm. Three hundred microliters of supernatant
was mixed with 500μl of color developing solution, incubated for
2min at room temperature, stopped with 500 Stop Solution, and
incubated for 5min at room temperature before read at 636 nm.
The ATP level was calculated as
ATP (μmol=g protein) = (ODs   ODc) = (ODsd   ODb)
 103μmol=L  dilution
 Concs (g protein=L)
where ODs was OD value of the sample, ODc was OD value of
control, ODsd was OD value of standard, ODb was OD value
of blank, dilution was the fold sample was diluted before assay,
and Concs was the concentration of the sample. The relative ATP
level was calculated against wild-typemice treated with shControl
and PBS.
Analysis of the ROS Level in
Mouse Skeletal Muscle
Muscle ROS level was measured with a commercial kit (E004,
Jianchen Biotech) according to the manufacturer’s instruction.
Briefly, mouse gastrocnemius muscle was homogenized in cold
phosphate buffer (100mmol/L, pH 7.1), centrifuged at 1000 g for
10min at 4°C. One hundred ninety microliters of supernatant was
mixed with 10μl of freshly made 1mmol/L DCFH-DC solution
and incubated at 37°C for 30min before measured at 500/525 nm
(Ex/Em). The relative ROS levels were presented with the ROS
level (OD525/mg protein) of wild-type mice that received shcon-
trol virus and PBS being set as 1.
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Statistical Analysis
The data was expressed as mean SE. The differences between
groups were analyzed by one-way Analysis of Variance using
Graphpad Prism 5. A p-value <0.05 was considered statistically
significant.
RESULTS
Silencing PGC-1α Potentiates ROS
Production in SOD1(G93A) Mice
As mitochondrial dysfunction and degeneration played a heavy
part in the onset of ALS in SOD1(G93A) mice, we first assessed
tissue ROS levels of mouse skeletal muscle. The ROS level of
SOD1(G93A) transgenic mice was almost fourfold of that of wild-
type mice, which was further increased to about 5.5-fold when
PGC-1αwas silenced in SOD1(G93A) transgenicmice (Figure 1).
Silencing PGC-1α in WT mice resulted in more than doubled
ROS level in muscle tissue (Figure 1). Treating SOD1(G93A)
transgenic and/or PGC-1α knockdown mice with rosiglitazone
reduced the ROS levels by 20–40%, respectively (Figure 1).
PGC-1α Functions as a Inhibitor of
Inflammation in SOD1(G93A) Mice
Next, we examined the levels of inflammatory cytokines in those
genetically manipulated mice since chronic-elevated ROS level
initiated inflammation. Silencing PGC-1α in WT mice resulted
in 70–100% increase of serum TNF-α, IL-1β, IL-6, and MIP-1α
levels (Figure 2). The levels of proinflammatory cytokines of
SOD1(G93A) mice were 2.4- to 3-fold of those of wild-type mice
(Figure 2), which were increased about 40% more when PGC-1α
was silenced in SOD1(G93A) mice (Figure 2). The increases of
serum proinflammatory cytokines were inhibited by rosiglitazone
treatment in those genetically manipulated mice (Figure 2).
PGC-1α Silencing Exacerbates Muscular
Fibrosis in SOD1(G93A) Mice
As muscular fibrosis was a major pathological feature of ALS,
the fibrosis level of mouse gastrocnemius muscle was assessed by
Sirius staining. KnockdownPGC-1α in wild-typemice resulted in
about threefold increase of fibrosis in skeletal muscles compared
to WT mice, which was attenuated by TZD treatment (Figure 3).
FIGURE 3 |Muscular fibrosis was increased by PGC-1α knockdown and SOD1(G93A). (A) The representative pictures of Sirius staining of gastrocnemius
muscle from wild-type or SOD1(G93A) mice received different treatment. (B) Quantitative analysis of collagen volume fraction of mouse gastrocnemius muscles. Data
were expressed as meanSD (n= 10). *p<0.05 vs wild-type mice treated with shControl and PBS; #p<0.05 vs SOD1(G93A) mice treated with shControl and
PBS; ^p<0.05 vs wild-type mice treated with shPGC-1α and PBS; and +p<0.05 vs SOD1(G93A) mice treated with shPGC-1α and PBS.
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FIGURE 4 |Muscle ATP level was reduced by PGC-1α knockdown and
SOD1(G93A) transgene. The ATP levels in mouse gastrocnemius muscle
were measured with a commercial colorimetric kit and expressed as levels
relative to wild-type mice received shcontrol and PBS. Data were expressed
as meanSD (n= 10). *p<0.05 vs wild-type mice treated with shControl
and PBS; #p<0.05 vs SOD1(G93A) mice treated with shControl and PBS;
^p<0.05 vs wild-type mice treated with shPGC-1α and PBS; and +p<0.05
vs OD1(G93A) mice treated with shPGC-1α and PBS.
The muscular fibrosis of SOD1(G93A) mice was more than 16.5
times of that of WT mice and further increased more than 40%
with PGC-1α silencing (Figure 3). Treatment of rosiglitazone
alleviated muscular fibrosis in all mutant mice (p< 0.01) even
though it did not have any effect in WT mice (Figure 3).
Muscular ATP Levels are Reduced by
SOD1(G93A) Transgene and/or PGC-1α
Knockdown
Next, we checked the ATP levels mouse gastrocnemius muscle
since PGC-1α and SOD1(G93A)were shown to regulate the num-
ber or function of mitochondria. The muscular ATP levels were
reduced about 20% in SOD1(G93A) transgenic mice and PGC-
1α knockdown mice, whereas it was decreased about another
10% inmice harboring both SOD1(G93A) transgene and PGC-1α
knockdown (Figure 4). Rosiglitazone treatment increasedmuscu-
lar ATP levels by more than 10% in mice with all genotypes tested
(Figure 4).
PGC-1α and SOD1(G93A) Regulate Genes
Involved in Metabolism, Antioxidant, and
Inflammation
The expression pattern of genes involved in energy metabolism
and inflammation in mouse gastrocnemius muscle were assessed
to evaluate the effects of PGC-1α silencing in combination
with SOD1(G93A) transgenic on these physiological processes.
Silencing PGC-1α drastically down-regulated SOD1 (Figure 5C),
UCP2 (Figure 5D), and cytochrome C (Figure 5E) expres-
sion. On the other hand, SOD1(G93A) transgenic significantly
reduced the mRNA levels of PGC-1α (Figure 5A), PGC-1β
(Figure 5B), endogenous SOD1 (Figure 5C), UCP2 (Figure 5D),
and cytochrome C (Figure 5E), whereas markedly increased NF-
κB mRNA level (Figure 5F) was in gastrocnemius muscle com-
pared to WT mice. Knockdown PGC-1α further strengthened
those changes, while TZD treatment showed a trend of partially
counteracting those changes (Figure 5). The protein levels of
aforementioned genes were generally consistent with their corre-
sponding mRNA levels (Figure 5G).
Decreased PGC-1α Results in Increased
Free NF-κB
As inflammatory responses and the injuries caused by inflam-
mation played a critical part in ALS pathogenesis, we tested if
PGC-1α was directly involved in the regulation of inflammation.
After immunoprecipitation of total protein of mouse gastrocne-
mius muscles using antibodies against NF-κB subunits p65 and
p50, PGC-1α was detected in the immunocomplexes of NF-κB,
whereas it was not precipitated by IgG control (Figure 6). More-
over, compared to WT mice, the amount of precipitated PGC-
1α from SOD1(G93A) and/or shPGC-1α mice was significantly
decreased by antibodies against either NF-κB subunits p65 or
p50 even though the amount of p65 and p50 precipitated from
the mutant mouse samples was higher than that of WT mouse
(Figure 6).
DISCUSSION
SOD1(G93A) transgene and PGC-1α knockdown individually or
additively inhibited the expression of genes involved in oxidative
metabolism (cytochrome C), antioxidant (SOD1), mitochondria
biogenesis (PGC-1α and PGC-1β), and uncoupling (UCP2) but
up-regulated inflammation gene (NF-κB) in mouse gastrocne-
mius muscles, which led to reducedmuscular ATP levels, elevated
ROS level, increased inflammation and muscular fibrosis.
The onset and progression of ALS involved many pathological
changes other than the death of motor neurons. The activation
of microglia and the progression of non-autonomous death of
motoneurons were significantly slowed down by reducing mutant
SOD1 in astrocytes (Yamanaka et al., 2008) andmicroglia (Boillée
et al., 2006) of SOD1(G37R) mice. Deletion of the tumor necrosis
factor-like weak inducer of apoptosis (Tweak) in SOD1(G93A)
transgenic mice significantly reduced microgliosis and inflam-
mation, and ameliorated ALS-associated pathological changes in
skeletal muscles (Bowerman et al., 2015). Skeletal muscle atro-
phy and denervation were shown to precede the loss of motor
axons from the ventral root and the death of motor neurons
(Fischer et al., 2004). Moreover, as one of the most energy con-
suming tissues, skeletal muscle is essential for maintaining the
metabolic homeostasis (Palamiuc et al., 2015) and is the pri-
mary target of the cytotoxicity of mutant SOD1 (Dobrowolny
et al., 2008; Wong and Martin, 2010). In SOD1(G86R) trans-
genic mice, blocking muscular metabolism switch from glucose
to lipids by inhibiting pyruvate dehydrogenase kinase 4 activity
with dichloroacetate increased PGC-1α level, reduced oxidative
Frontiers in Aging Neuroscience | www.frontiersin.org October 2015 | Volume 7 | Article 2045
Qi et al. PGC-1α in ALS
FIGURE 5 | The expression of genes related to energy metabolism, oxidative stress, and inflammation was changed in mice with SOD1(G93A)
transgene and/or PGC-1α knockdown. The mRNA levels of PGC-1α (A), PGC-1β (B), SOD1 (C), UCP2 (D), Cyt C (E), and NF-κB (F) were analyzed with
real-time qPCR and protein levels (G) with Western blot. Data were expressed as meanSD (n= 10). *p<0.05 vs wild-type mice treated with shControl and PBS;
#p<0.05 vs SOD1(G93A) mice treated with shControl and PBS; ^p<0.05 vs wild-type mice treated with shPGC-1α and PBS; and +p<0.05 vs SOD1(G93A) mice
treated with shPGC-1α and PBS.
FIGURE 6 | PGC-1α physically interacted with NF-κB. The total protein of mouse gastrocnemius muscle was immunoprecipitated with antibody against NF-κB
p65, NF-κB p50, or IgG and immunoblotted with specified antibodies. PGC-1α was co-precipitated with NF-κB complex by antibodies against NF-κB p65 (A) and
p50 (B) but not by control IgG. Tg, SOD1(G93A) transgenic; shPGC, shPGC-1α.
stress, and ultimately improved the disease conditions (Palamiuc
et al., 2015). Mice with muscle specific SOD1(G37R) transgenic
progressively developed muscular atrophy with myofiber loss
and muscle cell apoptosis, microgliosis, neuromuscular junction
abnormalities, motoneuron distal axonopathy, and eventually
death of motor neurons (Wong and Martin, 2010), indicat-
ing that ALS might originate from pathogenesis of skeletal
muscle.
Muscular hypermetabolism, weight loss, fat mass reduction,
and switching energy production from glycolysis to lipid con-
sumption were presented in ALS patients and ALS mouse models
(Dupuis et al., 2004, 2011; Dorst et al., 2011; Palamiuc et al., 2015).
Increased serum lipid levels showed a protective effect in ALS
patients (Dupuis et al., 2008; Dorst et al., 2011) and SOD1(G93A)
mice (Dupuis et al., 2004), which might be due to provid-
ing increased energy sources. These changes might be resulted
from the perturbation of the link between PPARγ-regulated lipid
metabolism and mitochondrial oxidative phosphorylation (Capi-
tanio et al., 2012), suggesting that effective ALS intervention may
be required to coordinate lipid oxidation with the increase of
mitochondrial number (PGC-1α) and the improvement of the
integrity and efficiency of mitochondria (Liu et al., 2011).
In this study, we showed that PGC-1α silencing in
SOD1(G93A) mice compounded with mutant SOD1 to cause
increased oxidative stress, inflammation, energy deficiency, and
massive muscular fibrosis. These pathological changes could be
attenuated by peroxisome proliferator-activated receptor gamma
(PPARγ) agonist TZDs. By summarizing our data and previously
reported results, we postulated that mutant SOD1 and/or
PGC-1α silencing might have several effects on the skeletal
muscles (Figure 7). First, SOD1(G93A) transgene and PGC-1α
knockdown caused the perturbation of metabolism and energy
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FIGURE 7 | A proposed model for the actions of PGC-1α and
SOD1(G93A) in ALS pathogenesis. PGC-1α orchestrates mitochondria
biogenesis and antioxidant enzymes while inhibits NF-κB activity. Knockdown
PGC-1α causes ATP deficiency and elevated oxidative stress. SOD1(G93A)
inhibits PGC-1α pathway and antioxidants among others. Reduced ATP level,
reduced antioxidants, and increased oxidative stress cause inflammation,
neuron degeneration, and myopathy, which promotes the progression of ALS.
homeostasis due to mitochondrial deficiency and abnormal
oxidative metabolism (Wu et al., 1999; Liang and Ward, 2006;
Róna-Vörös and Weydt, 2010; Palamiuc et al., 2015). Second,
oxidative stress was increased due to the reduced expression of
antioxidant enzymes and uncoupling proteins as well as mito-
chondrial malfunction (Wu et al., 1999; Liu et al., 2002; Róna-
Vörös andWeydt, 2010) in SOD1(G93A) transgenic and/or PGC-
1α knockdown mice. Third, inflammatory responses towards
ROS and other stimuli were augmented since NF-κB was released
from the inhibitory complex with PGC-1α due to the reduction
of PGC-1α level (Wang et al., 2007).
In conclusion, mitochondrial dysfunction and metabolism
imbalance were at the center of ALS pathogenesis. Mutant
SOD1 decreased PGC-1 expression and mitochondrial biogen-
esis, resulted in energy deficiency, increased ROS, caused mas-
sive inflammation and muscle fibrosis. Knockdown PGC-1α
exacerbated aforementioned changes. Strategies simultaneously
increasing mitochondria number, mitochondrial integrity, and
lipid metabolism may be explored for ALS treatment.
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